American Vanguard Reports Fourth Quarter & Full Year 2021 Results

Rhea-AI Summary

American Vanguard Corporation (NYSE: AVD) reported strong financial results for FY 2021, showing a 21% increase in net sales to $557 million compared to $459 million in FY 2020. Operating income rose 35% to $30.9 million, while net income increased to $18.6 million, translating to earnings per diluted share of $0.61. The company faced challenges like COVID-19 and supply chain disruptions but managed to maintain profit margins through price increases. A share repurchase program for up to one million shares was also announced, reflecting confidence in long-term success.

Positive

• Net sales increased by 21% to $557 million in FY 2021.
• Operating income rose 35% to $30.9 million.
• Earnings per diluted share increased to $0.61.
• Share repurchase program of up to one million shares announced.

Negative

• Operating income and EBITDA in 2020 included a one-time gain of $4.6 million.
• Reported a $3.3 million non-cash charge related to tax reserves affecting net income.

Announces Share Repurchase Plan

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- American Vanguard Corporation (NYSE: AVD) today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2021.

Fiscal 2021 Fourth Quarter Financial Highlights – versus Fiscal 2020 Fourth Quarter:

• Net sales were $159 million in 2021, compared to $141 million in 2020
• Operating income was $9.4 million in 2021, compared to $10.1 million in 2020
• EBITDA¹ of $14.8 million in 2021, compared to $17.1 million in 2020
• Both operating income and EBITDA from 2020 benefited from a one-time gain of $4.6 million due to bargain purchase accounting

Fiscal 2021 Full Year Financial Highlights – versus Fiscal 2020 Full Year:

• Net sales were $557 million in 2021, compared to $459 million in 2020
• Operating income was $30.9 million in 2021, compared to $22.9 million in 2020
• Net income was $18.6 million* in 2021, compared to $15.2 million in 2020
• Earnings per diluted share of $0.61* in 2021, compared to $0.51 in 2020
• EBITDA¹ of $56.8 million in 2021, compared to $47.5 million in 2020

*Net income and earnings per share for the full year period include the impact of a $3.3 million, one-time, non-cash charge relating to tax reserves (for net operating loss carryforwards) from the Company’s operations in Brazil. These NOLs may be taken as credits in future reporting periods subject to sufficient profitability from those operations.

With respect to the Company’s financial performance, CEO and Chairman, Eric G. Wintemute stated: “2021 proved to be a very successful year for AVD despite continuing challenges posed by COVID-19, supply chain disruptions and inflation. On an annual basis, our net sales increased by 21%, operating income was up about 35%, EBITDA rose 20% and, but for the one-time, non-cash charge (which could potentially be reversed over time), our net income would have risen 44% and generated EPS of $0.72.

“The Company adapted to restrictive public health protocols, varying degrees of customer access limitations, and remote work processes in many operational and administrative functions. Throughout the year, we kept AMVAC manufacturing facilities fully functioning and sustained strong profit margins with price increases to offset inflationary costs. In addition, we strengthened our balance sheet, reduced inventory, increased net cash from operations, reduced debt and improved availability under our credit facility.”

Mr. Wintemute continued: “2021 results were driven by every part of our business. Our U.S. Crop business benefited from economic reopening and high crop commodity prices which resulted in strong demand for our products in corn, soybeans, cotton, potatoes, and many fruits and vegetables. The U.S. Non-Crop business experienced significant demand in mosquito control, commercial pest applications, horticulture/ornamental products and Envance Technologies’ licensing for consumer products. In addition, our International business saw expanded presence in Australia, increased penetration of our biological offerings and solid performance from our Central and South American groups.”

Mr. Wintemute concluded: “Looking forward, we believe that our Company is situated well in both domestic and international markets. We are currently optimistic about the prospects for 8-11% revenue growth in 2022 and are targeting gross profit margins to remain strong (38 to 40% of net sales), net income to increase by 60-70% and operating expenses to be between 31% and 33% of net sales. On a very solid core business foundation, we will continue to develop our key strategic growth initiatives in Green Solutions and SIMPAS/Ultimus technologies. We look forward to giving you a more detailed presentation during our upcoming earnings call.”

In addition, the Company announced that its board of directors has approved a program for the repurchase of up to one million shares of common stock within the requirements of Exchange Act Rule 10b-18 over the course of the next year. With respect to the repurchase program, Mr. Wintemute stated, “This authorization reflects the strong confidence that our board places in the company’s long-term success. This program also serves, in part, to offset the expansion of outstanding shares resulting from equity awards that we make to our workforce.”

Conference Call

Eric Wintemute, Chairman & CEO, Bob Trogele, EVP & COO and David T. Johnson, VP & CFO, will conduct a conference call focusing on the financial results and strategic themes…at 4:30 pm ET on March 8, 2022. Interested parties may participate in the call by dialing 201-493-6744. Please call in 10 minutes before the call is scheduled to begin and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company’s web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company’s web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® and Russell 3000® Indexes and the Standard & Poor’s Small Cap 600 Index. To learn more about American Vanguard, please reference the Company’s web site at www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release.

CONSOLIDATED BALANCE SHEETS December 31, 2021 and 2020 (In thousands, except share data) (Unaudited)
		2021				2020
Assets
Current assets:
Cash and cash equivalents		$	16,285			$	15,923
Receivables:
Trade, net of allowance for doubtful accounts of $3,938 and $3,297, respectively			149,326				130,029
Other			9,595				6,969
Total receivables, net			158,921				136,998
Inventories, net			154,306				163,784
Prepaid expenses			12,488				10,499
Income taxes receivable			—				3,046
Total current assets			342,000				330,250
Property, plant and equipment, net			66,111				65,382
Operating lease right-of-use assets			25,386				12,198
Intangible assets, net of amortization			197,841				197,514
Goodwill			46,260				52,108
Other assets			16,292				20,077
Deferred income tax assets, net			270				2,764
Total assets		$	694,160			$	680,293
Liabilities and Stockholders’ Equity
Current liabilities:
Current installments of other liabilities		$	802			$	2,647
Accounts payable			67,140				59,253
Deferred revenue			63,064				43,611
Accrued program costs			63,245				45,441
Accrued expenses and other payables			20,745				16,184
Income taxes payable			3,006				—
Operating lease liabilities, current			5,059				4,188
Total current liabilities			223,061				171,324
Long-term debt, net of deferred loan fees			52,240				107,442
Other liabilities, excluding current installments			5,335				9,054
Operating lease liabilities, long-term			20,780				8,177
Deferred income tax liabilities, net			20,006				23,560
Total liabilities			321,422				319,557
Commitments and contingent liabilities
Stockholders’ equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued			—				—
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 34,248,218 shares in 2021 and 33,922,433 shares in 2020			3,426				3,394
Additional paid-in capital			101,450				96,642
Accumulated other comprehensive loss			(13,784	)			(9,322	)
Retained earnings			304,385				288,182
			395,477				378,896
Less treasury stock at cost, 3,361,040 shares in 2021 and 3,061,040 in 2020			(22,739	)			(18,160	)
Total stockholders’ equity			372,738				360,736
Total liabilities and stockholders’ equity		$	694,160			$	680,293

CONSOLIDATED STATEMENTS OF OPERATIONS Years ended December 31, 2021, 2020 and 2019 (In thousands, except per share data) (Unaudited)
		2021				2020				2019
Net sales		$	556,872			$	458,704			$	468,186
Cost of sales			(343,629	)			(286,114	)			(290,832	)
Gross profit			213,243				172,590				177,354
Operating expenses			(182,468	)			(154,339	)			(151,133	)
Bargain purchase gain on business acquisition			171				4,657				—
Operating income			30,946				22,908				26,221
Change in fair value of equity investments, net			(790	)			717				—
Other income			672				—				—
Interest expense, net			(3,687	)			(5,178	)			(7,209	)
Income before provision for income taxes and loss on equity method investment			27,141				18,447				19,012
Provision for income taxes			(8,166	)			(3,080	)			(5,202	)
Income before loss on equity method investment			18,975				15,367				13,810
Less loss from equity method investment			(388	)			(125	)			(209	)
Net income		$	18,587			$	15,242			$	13,601
Earnings per common share—basic		$	0.62			$	0.52			$	0.47
Earnings per common share—assuming dilution		$	0.61			$	0.51			$	0.46
Weighted average shares outstanding—basic			29,811				29,450				29,030
Weighted average shares outstanding—assuming dilution			30,410				29,993				29,656

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES ANALYSIS OF SALES For the years and quarters ended December 31, 2021 and 2020 (Unaudited)
	For the quarters ended December 31,							For the years ended December 31,
	2021			2020				2021				2020
Net sales:
U.S. crop	$	78,034		$	68,402			$	263,632			$	211,357
U.S. non-crop		19,588			16,811				78,605				60,367
Total U.S.		97,622			85,213				342,237				271,724
International		61,187			55,535				214,635				186,980
Total net sales	$	158,809		$	140,748			$	556,872			$	458,704
Gross profit:
U.S. crop	$	31,828		$	27,175			$	109,568			$	92,723
U.S. non-crop		8,823			6,736				37,443				27,842
Total U.S.		40,651			33,911				147,011				120,565
International		18,258			16,727				66,232				52,025
Total gross profit	$	58,909		$	50,638			$	213,243			$	172,590

CONSOLIDATED STATEMENTS OF CASH FLOWS Years ended December 31, 2021, 2020 and 2019 (In thousands) (Unaudited)
		2021				2020				2019
Increase cash
Cash flows from operating activities:
Net income		$	18,587			$	15,242			$	13,601
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment and intangible assets			22,229				19,902				18,643
Loss on disposal of property, plant and equipment			194				119				—
Amortization of other long-term assets			3,943				3,947				3,983
Accretion of discounted liabilities			(8	)			9				72
Amortization of deferred loan fees			367				300				224
Provision for bad debts			649				1,002				1,035
Loan principal and interest forgiveness			(672	)			—				—
Fair value adjustment of contingent consideration			758				250				(4,120	)
Decrease in environmental liability			(167	)			(1,155	)			—
Stock-based compensation			6,880				6,561				7,160
Increase (decrease) in deferred income taxes			(1,133	)			969				2,616
Changes in liabilities for uncertain tax positions or unrecognized tax benefits			(1,783	)			(2,092	)			263
Change in equity investment fair value			790				(717	)			—
Loss from equity method investment			388				125				209
Bargain purchase gain			(171	)			(4,657	)			—
Net foreign currency adjustment			(225	)			126				275
Changes in assets and liabilities associated with operations, net of business combinations:
(Increase) decrease in net receivables			(24,347	)			15,407				(11,513	)
Decrease in inventories			8,130				7,421				3,817
(Increase) decrease in income tax receivable, net			6,051				(287	)			(6,855	)
(Increase) decrease in prepaid expenses and other assets			(3,354	)			140				(876	)
Increase in net operating lease liability			286				18				149
Increase (decrease) in accounts payable			8,783				(8,199	)			(7,912	)
Increase (decrease) in deferred revenue			19,280				36,803				(13,355	)
Increase (decrease) in accrued program costs			17,877				(2,517	)			5,797
Increase (decrease) in other payables and accrued expenses			3,986				1,607				(3,600	)
Net cash provided by operating activities			87,318				90,324				9,613
Cash flows from investing activities:
Capital expenditures			(9,518	)			(11,249	)			(12,985	)
Acquisitions of businesses and product lines			(10,000	)			(19,342	)			(37,972	)
Intangible assets			(524	)			(4,014	)			(3,880	)
Investment			—				(1,190	)			—
Net cash used in investing activities			(20,042	)			(35,795	)			(54,837	)
Cash flows from financing activities:
Net (payments) borrowings under line of credit agreement			(55,569	)			(41,624	)			51,900
Payment of contingent consideration			(1,301	)			(1,227	)			(850	)
Net receipt from the issuance of common stock under ESPP			743				721				716
Net receipt from the exercise of stock options			172				1,603				680
Net payment from common stock purchased for tax withholding			(2,955	)			(2,745	)			(1,113	)
Repurchase of common stock			(4,579	)			—				(2,604	)
Payment of cash dividends			(2,382	)			(1,168	)			(2,323	)
Net cash (used in) provided by financing activities			(65,871	)			(44,440	)			46,406
Net increase in cash and cash equivalents			1,405				10,089				1,182
Effect of exchange rate changes on cash and cash equivalents			(1,043	)			(747	)			(769	)
Cash and cash equivalents at beginning of year			15,923				6,581				6,168
Cash and cash equivalents at end of year		$	16,285			$	15,923			$	6,581

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES RECONCILIATION OF NET INCOME TO EBITDA Quarters ended December 31, 2021 and 2020 (Unaudited)
	2021				2020
Net income attributable to American Vanguard	$	4,874			$	7,908
Provision for income taxes		2,842				1,396
Interest expense, net		766				1,374
Depreciation and amortization		6,340				6,418
EBITDA2	$	14,822			$	17,096

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES RECONCILIATION OF NET INCOME TO EBITDA Years ended December 31, 2021 and 2020 (Unaudited)
	2021				2020
Net income attributable to American Vanguard	$	18,587			$	15,242
Provision for income taxes		8,166				3,080
Interest expense, net		3,687				5,178
Depreciation and amortization		26,366				23,968
EBITDA 2	$	56,806			$	47,468

__________________________
¹ Earnings before interest, taxes, depreciation, and amortization. EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company’s competitors) may define EBITDA differently.
² EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company’s competitors) may define EBITDA differently.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006294/en/

Company Contact:

American Vanguard Corporation

William A. Kuser, Director of Investor Relations

(949) 260-1200

williamk@amvac-chemical.com

Investor Representative

the Equity Group Inc.

www.theequitygroup.com

Lena Cati

Lcati@equityny.com

Source: American Vanguard Corporation

FAQ

What were American Vanguard's net sales for FY 2021?

American Vanguard reported net sales of $557 million for FY 2021.

How did American Vanguard's operating income for Q4 2021 compare to Q4 2020?

Operating income for Q4 2021 was $9.4 million, compared to $10.1 million in Q4 2020.

What is the earnings per share (EPS) for AVD in FY 2021?

Earnings per diluted share for AVD in FY 2021 was $0.61.

What challenges did American Vanguard face in 2021?

American Vanguard faced challenges from COVID-19, supply chain disruptions, and inflation.

What is the purpose of American Vanguard's share repurchase program?

The share repurchase program aims to reflect confidence in the company's long-term success and offset share expansion from equity awards.